Common TitlePROTEA
Official Title PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects
Phase Phase III
ClinicalTrials.gov NCT01448707
Treatments
Darunavir
Darunavir
Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)Categories Treatment-ExperiencedSwitch/SimplificationMonotherapy
Funding
IndustryJanssen
References
- Antinori A, Arribas J, Fehr J, et al. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. J Int AIDS Soc. 2014;17:19525.
- Antinori A, Clarke A, Svedhem-Johansson V, et al. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS. 2015;29:1811-20.
- Girard PM, Antinori A, Arribas JR, et al. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV Med. 2017;18:5-12.